Influenza Virus Vaccine Articles & Analysis
24 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. ...
Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
ByNuvonis
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a ...
ImmunAdd’s next-generation Saponin-based adjuvant IA-05 induced both humoral and cellular immunities in various vaccines, including those against COVID-19, influenza, and cancer. IA-05 is accessible via total chemical synthesis and does not rely on extracts from Quillaja Saponaria or any other tree. ...
Australian vaccine technology company BioDiem Ltd (“BioDiem”) announced that effective today, Mr Hugh Morgan AC, will step down from his non-executive director roles on the boards of BioDiem and its subsidiary, Opal Biosciences Ltd (“Opal”). Mr Hugh Morgan AC has been chairman of BioDiem since 2005 and is a major shareholder of the company. He is actively involved in many ...
If VOLT elects not to exercise its option, Cancer Research UK will have the right to take the programme forward in all cancer indications. Unlike preventative vaccines, such as the influenza vaccine, which is given to healthy people to protect them against future disease, VTP-600 is given to people who already have lung cancer. ...
David Hipkiss, Enesi Pharma CEO, commented: “ImplaVax® can reduce wastage, eliminate the need for cold-chain logistics, and allow for easier administration of vaccines – representing a potential paradigm shift in the deployment and reach of mass-immunisation programmes like those regularly undertaken for influenza. ...
– Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Micron’s Microneedle-Based Measles-Rubella Vaccine – ATLANTA, July 13, 2021 /PRNewswire/ – Micron Biomedical, Inc. (“Micron” or the “Company”), a leader in dissolving, microneedle-based vaccine and drug delivery, today announced that it has initiated a Phase 1/2 clinical ...
Knocking out all strains of the targeted virus with one swift strike—a universal vaccine—is the necessary approach. ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. Enesi Pharma (“Enesi”), an innovative biotechnology company developing ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
And the Nipah virus (which has seen documented transmission to humans from both pigs and bats) carries a mortality rate as high as 75%. ...
The unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. ...
Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax™ adjuvant, today announced a ...
These cells have robust activity against very aggressive difficult-to-treat cancer models; this is directly relevant to COVID-19- and Influenza-mediated ARDS because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected. ...
Under $6.745 Million Grant from the Bill & Melinda Gates Foundation ATLANTA, Sept. 1, 2020 /PRNewswire/ — Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6M) to continue clinical development of its microneedle-based technology for measles and rubella vaccination from the Bill & Melinda Gates Foundation. This work leverages Micron’s ...
Osivax, a clinical-stage biotech start’up focused on vaccines and based in Lyon (France), announces today the closing of a seed funding round of EUR 2.7 million. Osivax was recently created as a spin-off of the R&D department of Imaxio, a biotech company also based in Lyon. The objectives of the spin-off are to enable Osivax to focus on the development of the R&D platform and ...
Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans. This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836. Imaxio’s influenza vaccine ...
Imaxio, a biotech company specialized in immunology, announces today having received from the USPTO (United States Patent and Trademark Office) notices of allowance for two of its latest patent applications. Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these ...
The aim of the OPTIVAC project is to improve the efficacy of vaccines for seasonal influenza and current pandemics. To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate ...